

May 13, 2025

For Immediate Release:

MTI Ltd.

Representative: Toshihiro Maeta,
President and Chief Executive Officer
Listing: TSE Prime [9438]
Contact: Hiroshi Matsumoto,
Senior Managing Director
Tel: +81-3-5333-6323

Notice Regarding Differences between Forecasts and Actual Results for the First Half of the Fiscal Year, and Revisions to Full-Year Results Forecast

MTI Ltd. (hereinafter the “Company”) announces the differences between the forecast and actual results for the first half of the fiscal year ending September 30, 2025, and the revision to the full-year earnings forecast, as announced on January 31, 2025. Detail are as follows.

1. Revision of the consolidated results forecast

(1) Differences between forecasts and actual results for the first half of the fiscal year ending September 30, 2025 (October 1, 2024 – March 31, 2025)

	Net sales	Operating income	Ordinary income	Profit attributable to owners of parent	Net income per share
Previous announced forecast (A)	Millions of yen 14,000	Millions of yen 1,250 ~1,450	Millions of yen 1,300 ~1,500	Millions of yen 1,250 ~1,390	Yen 22.68 ~25.22
Current announced forecast (B)	14,885	1,639	1,721	1,757	31.82
Differences (B-A)	+885	+189~+389	+221~+421	+367~+507	
Differences (%)	+6.3	+13.1~+31.2	+14.8~+32.4	+26.4~+40.6	
(Reference) Actual results in the previous fiscal year (For the first half of the fiscal year ended September 30, 2024)	13,517	1,052	1,518	1,558	28.41

[Reasons for the differences]

Net sales exceeded the previously announced forecast, primarily due to strong performance across multiple segments. In the healthcare business, the number of pharmacies implementing the cloud-based medication history service reached a record high on a quarterly basis, as a result of the company's focus on expanding installations at medium- to large-sized pharmacy chains. In the School DX business, initial development revenue from public school projects outperformed the plan. In the Corporate DX support business, orders from major corporations remained steady.

Accordingly, operating income, ordinary income, and profit attributable to owners of parent also exceeded the previously announced forecasts.

**(2) Revision of the consolidated financial forecast for the full fiscal year ending September 30, 2025
(October 1, 2024 – September 30, 2025)**

	Net sales	Operating income	Ordinary income	Profit attributable to owners of parent	Net income per share
Previous announced forecast (A)	Millions of yen 28,500	Millions of yen 2,800 ~3,200	Millions of yen 2,900 ~3,300	Millions of yen 2,050 ~2,330	Yen 37.20 ~42.28
Current announced forecast (B)	29,400	2,800 ~3,200	2,900 ~3,300	2,050 ~2,330	37.04 ~42.10
Differences (B-A)	+900	—	—	—	
Differences (%)	+3.2	—	—	—	
(Reference) For the fiscal year ended September 30, 2024	27,669	2,394	2,827	2,363	43.05

[Reasons for the revisions]

Net sales has been revised upward in light of the variance between the actual results for the first half and the previously announced forecast. On the other hand, operating income remains unchanged from the previous forecast, as the company plans to invest in system development related to pharmacy DX and childcare DX within the healthcare business, and to strengthen its organizational structure in the school DX business. Accordingly, ordinary income and profit attributable to owners of parent also remain unchanged from the previous forecast.

<Points to consider concerning forecasts>

Matters stated in this material concerning results forecasts are based on assessments, assumptions and convictions derived from information available to the Company at the time when this material is published. They may differ significantly from actual results due to a variety of factors, including future economic conditions in Japan and overseas, changes in conditions for business operations in Japan and overseas, or uncertain factors and potential risks inherent in forecasts. Those risks and uncertain factors include unpredictable effects on results that may arise from future events.

Note: This document is a translation of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.

Contact information for inquiries

Investor Relations Office

E-mail: ir@mti.co.jp URL: <https://ir.mti.co.jp/eng/>